Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Frontline Lenvatinib vs Sorafenib in HCC

June 28th 2017

Second-Line Systemic Therapy in HCC

June 28th 2017

HCC: Managing Patients on Frontline Systemic Therapy

June 28th 2017

Transitioning to Systemic Therapy in HCC

June 28th 2017

Frontline SIRT vs Systemic Therapy in HCC

June 28th 2017

Initial Approaches in Locally Advanced HCC

June 28th 2017

Ablation vs Resection in Liver Cancer

June 28th 2017

Risk/Benefit of Expanding Liver Transplant Criteria

June 28th 2017

Impact of Liver Cirrhosis in HCC

June 28th 2017

Understanding BCLC Criteria in Liver Cancer Staging

June 28th 2017

Diagnosing HCC: When a Biopsy is Needed

June 28th 2017

Screening for HCC: Current and Emerging Biomarkers

June 28th 2017

Global Trends in HCC Risk Factors

June 28th 2017

Dr. Sangro on the Efficacy of Nivolumab in HCC

June 27th 2017

Bruno Sangro, MD, PhD, head of Hepatology Unit, Internal Medicine Department, Clinica Universidad de Navarra, discusses the efficacy of nivolumab (Opdivo) in patients with hepatocellular carcinoma (HCC).

Dr. Talamonti on Advantages with Minimally Invasive Surgery for Pancreatic Cancer

June 27th 2017

Mark S. Talamonti, MD, clinical professor, NorthShore University HealthSystem, discusses the advantages of minimally invasive surgery for patients with pancreatic cancer.

Dr. Pinato Discusses Intra-tumor Heterogeneity in Primary and Metastatic HCC

June 26th 2017

David J. Pinato, MD, PhD, NIHR Academic Clinical Lecturer in Medical Oncology, resident, Royal Brompton Hospital and Imperial College London, discusses an analysis of intra-tumor heterogeneity in primary and metastatic hepatocellular carcinoma (HCC).

Dr. Cheng on Phase III Findings of Lenvatinib in HCC

June 26th 2017

Ann-Lii Cheng, MD, Distinguished Professor, Department of Internal Medicine, National Taiwan University College of Medicine Director, Graduate Institute of Oncology, director, Department of Medical Oncology, National Taiwan University College of Medicine, discusses the phase III trial of lenvatinib (Lenvima) compared with sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).

Dr. Jun on the Results of a Study Investigating Cyptogenic Hepatocellular Carcinoma

June 23rd 2017

Tomi Jun, MD, Stanford University School of Medicine, discusses results of a multi-center study investigating patients with cyptogenic hepatocellular carcinoma (HCC).

Dr. Sohal on Perioperative mFOLFIRINOX in Pancreatic Adenocarcinoma

June 22nd 2017

Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses an ongoing study exploring mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.

Dr. Abou-Alfa on Trials Investigating Immunotherapy in HCC

June 22nd 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses trials investigating immunotherapy in hepatocellular carcinoma (HCC).